Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.dovepress.com/new-developments-in-the-management-of-head-and-neck-cancer-impact-of-p-peer-reviewed-fulltext-article-TCRM, but it redirected us to https://www.dovepress.com/new-developments-in-the-management-of-head-and-neck-cancer-impact-of-p-peer-reviewed-fulltext-article-TCRM. The analysis below is for the second page.

Title[redir]:
New developments in the management of head and neck cancer - impact of | TCRM
Description:
New developments in the management of head and neck cancer - impact of pembrolizumab Khalil Saleh, Roland Eid, Fady GH Haddad, Nadine Khalife-Saleh, Hampig RaphaΓ«l Kourie Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon Abstract: Head and neck squamous cell carcinoma (HNSCC), a heterogeneous group of upper aerodigestive tract malignancies, is the seventh most common cancer worldwide. Tobacco use and alcohol consumption were the most identified risk factors of HNSCC. However, human papilloma virus, a sexually transmitted infection, has been determined as another primary cause of HNSCC. Early-stage disease is treated with surgery or radiotherapy. Recurrent or metastatic HNSCC is associated with poor prognosis with a median overall survival of 10 months. The EXTREME protocol is commonly used in first-line setting. Recently, pembrolizumab, an anti-programmed death-1 agent, has been approved by the US Food and Drug Administration for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. It demonstrated a durable objective response rate with a good safety profile and quality of life. Many ongoing trials are evaluating the use of pembrolizumab for the treatment of HNSCC in various indications such as adjuvant and neoadjuvant setting, maintenance and recurrent disease, alone or in combination with chemotherapy, radiation and targeted therapy. Finding those biomarkers predictive of response to immune checkpoints inhibitors has been a major concern. However, markers have been identified, such as PD-L1 expression, human papilloma virus infection, interferon-Ξ³ signature score, microsatellite instability and neoantigen production. Keywords: epidemiology, HPV, pharmacokinetics, PD-1/PD-L1 inhibitors, immunotherapy, biomarkers

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Science
  • Insurance

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

🌟 Strong Traffic: 100k - 200k visitors per month


Based on our best estimate, this website will receive around 100,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {πŸ”}

cancer, pembrolizumab, patients, hnscc, head, neck, pdl, response, cell, risk, hpv, immune, oncol, treatment, chemotherapy, keynote, squamous, carcinoma, tobacco, hnc, reported, disease, tumor, hpvpositive, clin, recurrent, oral, alcohol, inhibitors, smoking, hncs, metastatic, median, checkpoint, tumors, phase, trial, life, expression, orr, advanced, consumption, human, infection, therapy, quality, incidence, study, press, clinical,

Topics {βœ’οΈ}

gov/news-events/cancer-currents-blog/2016/fda-pembrolizumab-hnscc org/press-office/press-releases/keynote-040-evaluates-pembrolizumab org/meeting-resources/esmo-2016/updated-safety gov/drugs/informationondrugs/approveddrugs/ucm528920 anti-programmed-death-receptor-1 treatment treatment-related adverse events downregulate t-cell activation express cytotoxic t-lymphocyte a-squamous-cell-carcinoma anti-pd1 checkpoint inhibitor including fast-track processing transforming growth factor-beta ipilimumab-refractory advanced melanoma anti-programmed death-1 agent dove medical press anti-pd-l-1-antibody epstein-barr virus-tumors virus-related cancer epidemic ifn-Ξ³ signature score gene ifn-Ξ³ signature anti-pd-l1 agent interferon-Ξ³ signature score neck cancer-systematic review manuscript login reach steady-state concentration recurrent squamous-cell carcinoma mismatch repair deficiency open-label study middle-aged white men positive pd-l1 status pd-l1 expression subgroups receiving platinum-based chemotherapy locally advanced disease favored authors neck-scchn-expansion-cohort pd-1/pd-l1 inhibitors evidence-based treatment options pd-1/pd-l1 pathway pd-l1 expression analysis hpv-negative hnc decreased squamous cell carcinoma pd-l1-positive hncs hpv-positive hnc tumors specific author pd-1/pd-l1 interaction randomised dose-comparison cohort cd8+ t-cells overexpressed/mutated antigens pd-1/pd-l2 interactions pd-l1-positive patients

Questions {❓}

  • Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
  • Why publish with us?

External Links {πŸ”—}(183)

Analytics and Tracking {πŸ“Š}

  • Google Analytics
  • Google Tag Manager
  • Google Universal Analytics

Libraries {πŸ“š}

  • jQuery

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Com/cm/ef49a3f1-d8c1-47d6-88fc-50e41130631f/airgap

6.05s.